By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIU, Jun; SHIRE, Steven J., filed on March 7, 2014, was made available online on February 19, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novartis AG. The following qu
Tekmira Pharmaceuticals Corporation, a leading developer of RNAi interference therapeutics today announced the voting results from its Special Meeting of Shareholders held Tuesday, March 3, 2015, in Vancouver, B.C. Shareholders voted 99.5% in favor of the Agreement and Plan of Merger, dated as of January 11, 2015, with OnCore Biopharma, Inc. and
Acceleron Pharma reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma. In a release, the Company noted that the preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology 2015 Genitourinar
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter and yearly 2014 financial results after market close on Monday, March 9th, 2015. AcelRx Pharmaceuticals, Inc
Release date- 03032015- ALLSCHWIL, SWITZERLAND- Actelion Ltd today announced the formal acceptance of the New Drug Application for selexipag by the US Food and Drug Administration. The NDA dossier for selexipag in the treatment of pulmonary arterial hypertension was submitted to the FDA on the 22nd December 2014. Jean-Paul Clozel, M.D. and Chief Ex
Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that its 2015 Annual Meeting of Shareholders will be held on Monday, June 8, 2015 at Acucela s headquarters in Seattle,..
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for vascular disorders with an emphasis on diseases of the eye, today announced publication of positive results from the company s Phase 1 b/2a clinical study of lead clinical candidate, AKB-9778, a Tie2 activator. The TIME-1 clinical r
Dublin- Research and Markets has announced the addition of the "African Pharmaceutical Directory 2015" directory to their offering. The market potential of the African pharmaceutical and biotechnology sector is enormous and business opportunities abound. If you need to source from, or sell to Pharmaceuticals, Biotechnology products, Biopharmaceutic
IRVINE, Calif.& AMSTERDAM Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new data from an ongoing study indicates the BluePrint functional molecular subtyping assay more accurately identifies molecular subgroups and may be a better guide for neoadjuvant treatment than standard, lo
By a News Reporter-Staff News Editor at Biotech Week A recently published clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe. The report, which is published in the J
"The FDA approval of NATRELLE INSPIRA round gel-filled implants exemplifies our commitment to scientific innovation and to meeting the dynamic needs of plastic surgeons and their patients," said Scott Whitcup, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan. "In the past two years, Allergan has received
ALEXANDRIA, Va., March 4 Ampio Pharmaceuticals, Greenwood Village, Colorado, has been assigned a patent developed by David Bar-Or, Englewood, Colorado, Raphael Bar-Or, Denver, and Richard Shimonkevitz, Larkspur, Colorado, for the "treatment of T-cell mediated diseases." The patent application was filed on Nov. 14, 2012. Written by Amal Ahmed; edi
ANI Pharmaceuticals, Inc. announced today that it will present at the 27th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On March 9, 2015 at 11 AM PT, Arthur S. Przybyl, President and CEO, will give the Company's presentation, which is posted on the Investor section of ANI's website at www.anipharmaceuticals.com. ANI Ph
By a News Reporter-Staff News Editor at Biotech Week Anika Therapeutics, Inc. announced that it has appointed Glenn R. Larsen, Ph.D., as a new independent member of its Board of Directors. Anika's Board of Directors has voted to nominate Dr. Larsen for election by the stockholders at the 2015 Annual Meeting. About Anika Therapeutics, Inc. Headqua
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on February 13, 2015. The SEC file number is 0001100412-15-000010.. A U.S. Securities and Exchange Commission filing is a for
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on February 17, 2015. The SEC file number is 0001193805-15-000208.. A U.S. Securities and Exchange Commission filing is a for
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead s president and chief executive officer Christopher Anzalone, Ph.D., will present at the 2015 Barclays Global Healthcare Conference on March 11, 2015 at 1:35 p.m. EST. Arrowhead Research Corporation is a...
ASTRAZENECA TO PARTICIPATE IN US FDA ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE AstraZeneca today announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on 14 April 2015 to discuss the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in P
Release date- 03032015- Kortrijk, Belgium- Healthcare imaging specialist Barco announces the launch of a new diagnostic display system: Nio 5 MP LED. 'The Nio 5 MP LED fits into Barco's new family of diagnostic display systems, featuring a clean and modern design and a smaller desktop footprint for more reading comfort,' comments Lynda Domogalla, V
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, will report fourth quarter and year-end 2014 financial results after the close of U.S. financial markets on Wednesday, March 11, 2015. Bellicum management will host a webcast and conference call at 5:00 p.
BioClinica's eClinical technologies include: the Microsoft Office-Smart OnPoint CTMS; Express EDC; Trident IRT; predictive clinical supply Optimizer; and Compass, the risk-based intelligent monitoring solution. Martijn Princen, BioClinica's Head of European eClinical Sales, remarked, "The event gives us another window into the pressing needs of our
By a News Reporter-Staff News Editor at Biotech Week This webinar will discuss new Biologics, Biosimilars, and Biobetters programs using case studies to illustrate strategy choices and the similarities and differences between each program. Join speakers Judith Newmark, Program Manager, Pharmacology/Toxicology/Ocular at Toxikon Corporation, and...
Release date- 03032015- Ingelheim, Germany,- Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency, U.S. Food and Drug Administration and Health Canada.1. 'The submissions for idarucizumab mark the first regulatory submissions for a specific reversal agent
Bristol-Myers Squibb Company today announced an approval of an additional indication for Opdivo by the U.S. Food and Drug Administration. Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Company Media:
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, is pleased to announce the appointment of Rong Chen MD, Ph.D. as Chief Medical Officer.